Johnson & Johnson (JNJ) Stock Price & Market Analysis

JNJ · NYSE · Drug Manufacturers - General

Last confirmed priceDelayed

$256.03

▼ -$2.63(-1.02%)4:00 PM ET - vs previous close

Quote as of Oct 2, 2026, 4:00 PM EDT

Regular-session close · Oct 2, 2026, 4:00 PM EDT.

Yahoo Finance · delayed, minutes not stated · as of Oct 2, 2026, 4:00 PM EDT · last confirmed

Last session21%

$255.12L Oct 2 '26$259.38H Oct 2 '26

52-week range74%

$182.94$281.07H Sep 2 '26

Long-term rangesAvailable history

Available history(2000-10-03)90%

$20.47L Mar 27 '01$281.07H Sep 2 '26

Available history: 2000-10-03–2026-10-02. This is the supplied data window, not a verified inception date. Range extremes use intraday highs/lows where supplied, otherwise closes. Provider-reported; adjustment basis unspecified. The separate 52-week range uses Yahoo Finance figures; its adjustment basis is unspecified.

Price chart

JNJ price action

Latest 1D session

Open$259.38High$259.38Low$255.12

Advanced chart. Historical closing observations. The quote is a separately timestamped trade; provider or adjustment differences can produce different values.

Page snapshot trade: $256.03 · Yahoo Finance · Oct 2, 2026, 4:00 PM EDT · unadjusted trade. Initial chart close: $256.03 · 2026-10-02 · Yahoo Finance · Provider-reported; adjustment basis unspecified. These observations are not interchangeable.

Enable the benchmark overlay to compare with QQQ over the selected range.

Loading price chart…

Session market context

Oct 2, 2026, 4:00 PM EDT

JNJStock · vs previous close: ↓ -1.02%
QQQNasdaq-100 ETF: ↑ +1.02%

Price comparisons describe market context; they do not establish the cause of a move.

Data freshness — last confirmed snapshot

Live provider data is not available for this symbol right now, so every market field below comes from the last confirmed snapshot, captured 6:16 PM EDT. These are not real-time prices, and nothing on this page has been re-checked against a provider since that capture.

What matters next

Next important events

Oct 13, 2026Next earningsFinnhub · Confirmed · Last verified 2026-10-03

Earnings calendar and report history

Countdown

10 days out

Loading upcoming events…

Reported fundamentals

JNJ research snapshot

Year ended Dec 28, 2025

Annual revenue

USD 94.19B

Sales for the fiscal year ended Dec 28, 2025. This is not trailing twelve-month revenue.

Revenue change

+6.0%

Change versus the fiscal year ended Dec 29, 2024.

Net profit margin

28.5%

Net income divided by revenue for the fiscal year ended Dec 28, 2025. This is not the trailing margin.

These reported results describe the business’s recent scale and profitability. Compare cash generation and valuation before forming an investment view; historical growth is not a forecast.

Explore statements →Estimates & scenarios →Source filing ↗

Company · Profile

About Johnson & Johnson (JNJ)

Sector, leadership, and how Johnson & Johnson earns its revenue.

Healthcare

Johnson & Johnson

NYSE · JNJ · US

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Company narrative is editorial context. Source observation date: 2026-10-03T00:05:56.630Z. Narratives and leadership records are excluded from current quality ratings.

Sector: Healthcare
Industry: Drug Manufacturers - General
Headquarters: New Brunswick, NJ, United States
Country: US
Founded: 1944
Employees: 141,700
CEO: Joaquin Duato
Exchange: NYSE

Business model & operating evidence

Company website ↗

AI business exposure

Revenue exposure: AI-specific revenue is not separated in the available company statements.
Capital-spending dependency: No reviewed quantitative dependency model is available.
Compute role: See the sourced business description; AI labels do not establish compute revenue.
Platform examples: An exhaustive, consistently defined product inventory is unavailable.
Ecosystem links: Supplier and customer links require reviewed disclosures.

Narrative versus numbers

Demand is expanding

Supporting observation: 6.6%

Year-over-year growth in the latest quarter. This is not the fiscal-year revenue change in the snapshot above. · SEC Companyfacts · 2026-06-28

Growth produces accounting profit

Supporting observation: 21.5%

Reported-period net margin. A positive figure supports accounting profitability, not cash generation. · SEC Companyfacts · 2026-10-03T12:39:24.480Z

The business generates cash after investment

Supporting observation: USD 7.3B

Latest reported free cash flow. It is not a forecast and it is not the fiscal-year snapshot. · SEC Companyfacts · 2026-06-28

These are explicit tests of individual claims, not an overall bull/bear rating. Demand growth can coexist with valuation, concentration and financing risk.

Operating measures

Revenue: $25.31Bquarter ended Jun 28, 2026
Gross margin: 68.2%quarter ended Jun 28, 2026
EPS: $2.27quarter ended Jun 28, 2026
Capital expenditure: $1.32Bquarter ended Jun 28, 2026
Free cash flow: $7.29Bquarter ended Jun 28, 2026
Free cash flow margin: 28.8%quarter ended Jun 28, 2026
Operating cash / net income: 1.56×quarter ended Jun 28, 2026
Revenue growth year over year: 6.6%quarter ended Jun 28, 2026

Leadership

CEO: Joaquin Duato

Source: Financial Modeling Prep · 2026-10-03T00:05:56.630Z

Ownership filings and insider activity

Competitors & comparisons

Direct competitors, industry comparables and thematic alternatives have different uses. Compare fiscal periods and business mix before comparing multiples.

Compare by investment question

Product or industry overlap; not identical economics.

Peer valuation versus growth

How to read this comparison

Further right means faster expected revenue growth. Higher means a higher price relative to forecast earnings. Compare companies with similar businesses and fiscal periods; a lower multiple alone does not mean a stock is cheap.

JNJ7.6% expected growth23.1× forward P/E

Growth compares the annual revenue estimate with the preceding fiscal-year actual. Fiscal periods differ across companies; the table below lists each period. Select a company to inspect its values.

Company	Forward P/E	Expected FY revenue growth / period	Forward EPS / trailing EPS growth
JNJ	23.11×	7.62%FY2026 period end 2026-12-31	28.37%
TMO	26.06×	7.44%FY2026 period end 2026-12-31	34.65%
ISRG	36.36×	16.81%FY2026 period end 2026-12-31	23.90%
LLY	30.93×	35.77%FY2026 period end 2026-12-31	23.87%
ILMN	50.98×	6.47%FY2026 period end 2026-12-31	-2.98%

Loading competitor research…

Related ETFs

Funds to research for sector and market exposure. A benchmark link does not by itself confirm a holding.

ETF	JNJ weight	Holdings checked
QQQ	Not in top holdings on file	2026-10-03

Loading fund exposure…

Governance & sustainability

Find proxy statements and annual reports

Read JNJ news & coverage

All data sources

Search the dated figures used for this view. Each entry identifies its units, reporting period and calculation status.

Browse all companies and funds

Research tools

Market closed

Regular hours: 9:30 AM–4:00 PM America/New_York

Next open: 2026-10-05 · 9:30 AM America/New_York

Exchange calendar includes scheduled holidays and early closes. Extended-session prices appear separately only when supplied by the quote source.